Brokerages forecast that Immatics (NASDAQ:IMTX – Get Rating) will announce earnings per share of $1.86 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Immatics’ earnings, with the highest EPS estimate coming in at $2.07 and the lowest estimate coming in at $1.65. Immatics reported earnings per share of ($0.41) in the same quarter last year, which would indicate a positive year-over-year growth rate of 553.7%. The company is expected to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Immatics will report full year earnings of ($0.21) per share for the current financial year, with EPS estimates ranging from ($1.91) to $0.72. For the next fiscal year, analysts expect that the firm will post earnings of ($1.77) per share, with EPS estimates ranging from ($2.32) to ($1.54). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Immatics.
Immatics (NASDAQ:IMTX – Get Rating) last posted its earnings results on Wednesday, March 23rd. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of $1.94 by ($2.24). The business had revenue of $17.99 million during the quarter, compared to the consensus estimate of $84.78 million. Immatics had a negative return on equity of 154.19% and a negative net margin of 260.05%.
IMTX stock traded down $0.25 during trading hours on Friday, hitting $7.47. The company’s stock had a trading volume of 98,260 shares, compared to its average volume of 109,963. The company has a market capitalization of $469.94 million, a PE ratio of -4.45 and a beta of 0.38. Immatics has a 12 month low of $6.48 and a 12 month high of $16.30. The stock has a 50 day moving average price of $7.91 and a two-hundred day moving average price of $10.12.
Institutional investors have recently modified their holdings of the company. Copernicus Capital Management LLC acquired a new position in Immatics during the 3rd quarter valued at $130,000. Sphera Funds Management LTD. acquired a new position in Immatics during the 3rd quarter valued at $10,401,000. MYDA Advisors LLC acquired a new position in Immatics during the 3rd quarter valued at $130,000. Northern Trust Corp acquired a new position in Immatics during the 4th quarter valued at $370,000. Finally, Citadel Advisors LLC acquired a new position in Immatics during the 2nd quarter valued at $347,000. Institutional investors and hedge funds own 36.61% of the company’s stock.
About Immatics (Get Rating)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
- Get a free copy of the StockNews.com research report on Immatics (IMTX)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.